Review of therapies for intermediate and advanced stage hepatocellular carcinoma, not suitable for curative therapies: a rapidly changing landscape

Abstract

Recent clinical trials and new agents have permitted greater clarity in the choice of effective agents for that majority of patients with hepatocellular carcinoma who have advanced disease at diagnosis and thus cannot be offered potentially curative resection, ablation or liver transplantation. The main treatment for these patients remains chemoembolization, although evidence for selective internal radiation therapy (SIRT) with SIR-Spheres or Theraphere, is beginning to suggest that the results with this may be comparable with less toxicity. Patients who have failed chemoembolization or SIRT or have metastatic disease at presentation are suitable for the multikinase inhibitor sorafenib (nexavar) or newly-approved lenvatinib (lenvima) as first line therapies. The choice between which of them to use first is not currently clear. Patients who have failed sorafenib can be offered a choice of FDA-approved regorafenib (stivarga) or immune checkpoint inhibitor nivolumab (opdivo) as second line agents. For that considerable percent of patients presenting with macroscopic portal vein thrombosis, the choice appears to be between multikinase inhibitor or SIRT, given the potential toxicity of chemoembolization in this setting. However, considering the potency of both nivolumab and regorafenib and the pipeline of new agents such as atezolizumab (tecentriq) in current clinical trials, including new immune checkpoint inhibitors, this landscape may change within a couple of years, especially if new evidence arises for the superior effectiveness of combinations of any of these agents over single agents.

Keywords

Hepatocellular carcinoma / advanced / kinase inhibitors / immune checkpoint inhibitors / transarterial chemoembolization / selective internal radiation therapy

References

[1] Pugh RN,Dawson JL,Williams R.Transection of the oesophagus for bleeding oesophageal varices..Br J Surg1973;60:646-9

[2] Minagawa M,Matsuyama Y,Makuuchi M.Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM staging systems in a cohort of 13,772 patients in Japan..Ann Surg2007;245:909-22 PMCID:PMC1876960

[3] Llovet JM,Bruix J.The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma..Liver Transpl2004;10:S115-20

[4] Carr BI,Geva R.Carr BI.Hepatocellular carcinoma: diagnosis and treatment..Medical Therapy of HCC.2016;New YorkSpringer International Press489-512

[5] White JA,Li P,McGuire BM.Current guidelines for chemoembolization for hepatocellular carcinoma: room for improvement?.Hepatol Commun2017;1:338-46 PMCID:PMC5721390

[6] Llovet JM.Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival..Hepatology2003;37:429-42

[7] Lo CM,Tso WK,Lam CM.Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma..Hepatology2002;35:1164-71

[8] Llovet JM,Montaña X,Coll S.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial..Lancet2002;359:1734-9

[9] Zhao M,Jiang H.Transarterial chemoembolization (TACE) with platrinum versus anthracyclenes for hepatocellular carcinoma: a meta analysis..Int J surg2018;53:151-8

[10] Xie ZB,Peng YC,Ma L.Systematic review comparing the safety and efficacy of conventional and drug eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma..Hepatol Res2015;45:190-200

[11] Yang DJ,Liu H,Tao GQ.Meta-analysis of transcatheter arterial chemoembolization plus radiofrequency ablation versus transcatheter arterial chemoembolization alone for hepatocellular carcinoma..Oncotarget2017;8:2960-70 PMCID:PMC5356855

[12] Pommergaard HC,Adam R,Salizzoni M.Locoregional treatments before liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry..Transpl Int2018;31:531-9

[13] Meyer T,Ma YT,James MW.Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial..Lancet Gastroenterol Hepatol2017;2:565-75

[14] Chao Y,Han G,Yang J.The combination of transcatheter arterial chemoembolization and sora- fenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial..Int J Cancer2015;136:1458-67

[15] European Association For The Study Of The Liver; European Organisation For Research And Treatment Of CancerEASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma..J Hepatol2012;56:908-43

[16] Salem R,Kulik L,Riaz A.Radioembolization results in longer time to progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma..Gzastroenterology2011;140:497-507 PMCID:PMC3129335

[17] Carr BI.Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients..Liver Transpl2004;10:S107-10

[18] Salem R,Carr BI,Geschwind JF.Yttrium-90 microspheres: radiation therapy for unresectable liver cancer..J Vasc Interv Radiol2002;13:S223-9

[19] Lau WY,Ho S,Chan M.Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study..Br J Cancer1994;70:994-9 PMCID:PMC2033550

[20] Edeline J,Campillo-Gimenez B,Pracht M.Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis..Eur J Nucl Med Mol Imaging2016;43:635-43

[21] Kulik LM,Mulcahy MF,Atassi B.Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis..Hepatology2008;47:71-81

[22] Spreafico C,Vaiani M,Bhoori S.Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion..J Hepatol2018;68:724-32

[23] Chow PKH,Tan SB,Khasbazar A.SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma..J Clin Oncol2018;36:1013-21

[24] Kulik L,Koppe S,Mulcahy MF.Prospective randomized pilot study of Y90+/- sorafenib as a bridge to transplantation in hepatocellular carcinoma..J Hepatol2014;61:309-17

[25] Lobo L,Picado O,Pendola F.Unresectable hepatocellular carcinoma: radioembolization versus chemoembolization: a systematic review and meta-analysis..Cardiovasc Intervent Radiol2016;39:1580-8

[26] Gabr A,Ali R,Atassi R.Comparative study of post-transplant outcomes of hepatocellular carcinoma patients treated with chemoembolization or radioembolization..Eur J Radiol2017;93:100-6

[27] Llovet JM,Mazzaferro V,Gane E.Sorafenib in advanced hepatocellular carcinoma..N Engl J Med2008;359:378-90

[28] Cheng AL,Chen Z,Qin S.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial..Lancet Oncol2009;10:25-34

[29] Peng S,Xu F,Xu Y.An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma..PLoS One2014;9:e112530 PMCID:PMC4251972

[30] Wu FX,Bai T,Yang TB.The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma..BMC Cancer2017;17:645 PMCID:PMC5596482

[31] Liu L,Wang M,Cai G.Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis..PLoS One2014;9:e91124 PMCID:PMC3961236

[32] Zhong JH,Xiang BD.Adjuvant sorafenib in hepatocellular carcinoma: a cautionary comment of STORM trial..World J Hepatol2016;8:957-60 PMCID:PMC4990759

[33] Kudo M,Qin S,Ikeda K.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial..Lancet2018;391:1163-73

[34] Bruix J,Merle P,Huang YH.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial..Lancet2017;389:56-66

[35] Refolo MG,Lippolis C,Cavallini A.IGF-1R tyrosine kinase inhibitors and vitamin K1 enhance the antitumor effects of regorafenib in HCC cell lines..Oncotarget2017;8:103465-76 PMCID:PMC5732742

[36] El-Khoueiry AB,Yau T,Kudo M.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial..Lancet2017;389:2492-502

[37] Abou-Alfa GK,Cheng AL,Rimassa L.Cabozantinib in patients with advanced and progressing hepatocellular carcinoma..N Engl J Med2018;379:54-63

[38] Chau I,Borg C,Seitz JF.Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: patient-focused outcome results from the randomised phase III REACH study..Eur J Cancer2017;81:17-25

[39] Kudo M,Ohkawa S,Masumoto A.Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial..J Gastroenterol2017;52:494-503

[40] Carr BI.Hepatocellular carcinoma extrahepatic metastasis in relation to tumor size and alkaline phosphatase levels..Oncology2016;90:136-42

[41] Finn RS,Farah W,Zaiem F.Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: a systematic review and met-analysis..Hepatology2018;67:422-35

[42] Han K,Ko GY,Sung KB.Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: a comprehensive review..World J Gastroenterology2016;22:407-16 PMCID:PMC4698503

[43] Mazzaferro V,Bhoori S,Morosi C.Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study..Hepatology2013;57:1826-37

[44] Heimbach JK,Finn RS,Abecassis MM.AASLD Guidelines for the treatment of hepatocellular carcinoma..Hepatology2018;67:358-80

[45] Akkiz H,Kuran S,Üsküdar O.Macroscopic portal vein thrombosis in HCC patients..Canadian J Gastroenterol Hepatol2018; PMCID:PMC6020651

[46] Cheng S,Cai J.Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition..Oncotarget2017;8:8867-76 PMCID:PMC5352449

[47] Wang K,Chen MS,Sun BC.Multimodality treatment for hepatocellular carcinoma with portal vein tumor thrombus: a large-scale, multicentre, propensity matching score analysis..Medicine (Baltimore)2016;95:e3015 PMCID:PMC4839896

[48] Liu L,Wang M,Cai G.Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis..PLoS One2014;9:e91124 PMCID:PMC3961236

[49] Zhang X,Wang M,Ye X.Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis..Oncotarget2017;8:29416-27 PMCID:PMC5438741

[50] Carr BI,Giannini EG,Ciccarese F.Identification of two clinical hepatocellular carcinoma patient phenotypes from results of standard screening parameters..Semin Oncol2014;41:406-14 PMCID:PMC4109657

[51] Rimassa L,Peck-Radosavljevic M,Zagonel V.Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study..Lancet Oncol2018;19:682-93